ASH-41020, a dendranib nanomedicine, reduces disease severity in EAE preclinical models
Sep. 5, 2023
Researchers from Ashvattha Therapeutics LLC recently reported on ASH-41020, a new dendranib compound acting as a CSF-1R inhibitor with anti-inflammatory and immunomodulatory effects.
